



## Concerns on Antibiotic resistance

### What is the issue?

\n\n

India is yet to regulate antibiotic use and it serves as a cause of concern.

\n\n

### What are the recent happenings?

\n\n

\n

- A recent investigation found that the world's largest veterinary drug-maker, Zoetis, was selling antibiotics as growth promoters to poultry farmers in India.

\n

- It had stopped the practice in the U.S, since the U.S. banned the use of antibiotics as growth-promoters in early 2017.

\n

- Even then, India is yet to regulate antibiotic-use in poultry.

\n

- Technically, the drug-maker was doing nothing illegal and complying with local regulations in both countries.

\n

- But such reasoning is self-defeating, because antibiotic-resistance does not respect political boundaries.

\n

\n\n

### What is the status of India?

\n\n

\n

- India stands to lose the most from antibiotic resistance is India, given that its burden of infectious disease is among the highest in the world.

\n

- According to a 2016 PLOS Medicine paper, 416 of every 100,000 Indians die of infectious diseases each year.  
\n
- This is more than twice the U.S.'s crude infectious-disease mortality-rate in the 1940s, when antibiotics were first used there.  
\n
- Thus if these miracle drugs stop working, no one will be hit harder than India.  
\n
- This creates a need for a tighter regulatory regime in the country.  
\n

\n\n

### What are the steps taken so far?

\n\n

- There are three major sources of antibiotic resistance -  
\n

\n\n

1. Overuse of antibiotics by human beings  
\n
2. Overuse in the veterinary sector  
\n
3. Environmental antibiotic contamination due to pharmaceutical and hospital discharge.  
\n

\n\n

- To tackle the first source, India classified important antibiotics under **Schedule H1** of the **Drugs and Cosmetics Rules 1945**.  
\n
- Under the Rules, drugs specified under Schedule H and Schedule X are required to be sold by retail on the prescription of a Registered Medical Practitioner only.  
\n
- Even then, Schedule H1 drugs are freely available in pharmacies, with state drug-controllers unable to enforce the law widely.  
\n
- To tackle the second source, India's 2017 **National Action Plan on Antimicrobial Resistance** did talk about restricting antibiotic use as

growth promoters.

\n

- But the lack of progress on this front allows companies to sell last-resort drugs to farmers over the counter.

\n

- To tackle the third source, the same national action plan spoke about regulating antibiotics levels in discharge from pharmaceutical firms.

\n

- For instance, Hyderabad's pharmaceutical industry has been pumping massive amounts of antibiotics into local lakes, rivers and sewers.

\n

- This has led to an explosion in resistance genes in these waterbodies.

\n

- Still, India is yet to introduce standards for antibiotics in waste water, which means antibiotic discharge in sewage is not even being monitored regularly.

\n

\n\n

## **What should be done?**

\n\n

\n

- Antibiotics lose their efficacy against deadly infectious diseases worldwide.

\n

- According to a 2013 estimate, around 58,000 newborns die in India each year due to sepsis from resistant bacteria.

\n

- As the country takes its time to formulate regulations, the toll from antibiotic-misuse is growing at an alarming rate.

\n

- The issue also seems to be business as usual for governments, private corporations and individuals who have the power to stall a post-antibiotic health complication.

\n

- Thus there is a need for stricter regulations and regulated monitoring, else India will have no one to blame but itself.

\n

\n\n

\n\n

**Source: The Hindu**

\n



# IAS PARLIAMENT

*Information is Empowering*

A Shankar IAS Academy Initiative